

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 July 2003 (31.07.2003)


PCT

(10) International Publication Number
WO 03/061620 A3

- (51) International Patent Classification⁷: A61K 47/48 (74) Agent: HIRONS, Robert, G.; Ridout & Maybee LLP, One Queen Street East, Suite 2400, Toronto, Ontario M5C 3B1 (CA).
- (21) International Application Number: PCT/CA03/00066
- (22) International Filing Date: 21 January 2003 (21.01.2003) (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 2,368,656 21 January 2002 (21.01.2002) CA
- (71) Applicant (*for all designated States except US*): VASO-GEN IRELAND LIMITED [IE/IE]; Shannon Airport House, Shannon, Co. Clare (IE).
- (72) Inventors; and (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (75) Inventors/Applicants (*for US only*): BOLTON, Anthony, E. [GB/GB]; 7 Wyebank Grove, Bakewell, Derbyshire DE45 1BJ (GB). MANDEL, Arkady [CA/CA]; 277 Hidden Trail, North York, Ontario M2R 3S7 (CA).
- Published:
— with international search report

[Continued on next page]

(54) Title: PEPTIDE-CARRYING BODIES FOR IMMUNE RESPONSE



(57) Abstract: A composition of matter capable of producing an anti-inflammatory response in vivo in a mammal comprises bodies having a three-dimensional core structure of conformation and size from about 20nm to about 500 m and expressing or expressible on the surface thereof RGDS ligands which will react, optionally in the presence of adapter molecules, with at least one specific receptor wherein the binding of said ligand with said receptors produces an anti-inflammatory response in vivo in said mammal.

WO 03/061620 A3



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(88) Date of publication of the international search report:
16 October 2003

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 03/00066

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, MEDLINE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 840 691 A (EVERETT JEFFREY E ET AL) 24 November 1998 (1998-11-24) column 2, line 11-22, 41-44, 48-62 column 3, line 15-47 column 8, line 55 -column 9, line 65 ---	1-5, 9-13
X	LESTINI B J ET AL: "Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, VOL. 78, NR. 1-3, PAGE(S) 235-247 XP004329821 ISSN: 0168-3659 page 237 -page 239; figures 2,3 --- -/--	1-5, 9, 10, 12

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

27 June 2003

Date of mailing of the international search report

22/08/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Vermeulen, S

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>SJAASTAD MICHAEL D ET AL: "Feedback regulation of cell-substratum adhesion by integrin-mediated intracellular Ca-2+ signaling."</p> <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 91, no. 17, 1994, pages 8214-8218, XP002245778</p> <p>1994</p> <p>ISSN: 0027-8424</p> <p>page 8214</p> <p>---</p>	1-3
X	<p>ADDERLEY SHARON R ET AL: "Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation."</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 8, 25 February 2000 (2000-02-25), pages 5760-5766, XP002245779</p> <p>ISSN: 0021-9258</p> <p>cited in the application</p> <p>page 5761</p> <p>---</p>	1-3
A	<p>EP 0 298 820 A (INST NAT SANTE RECH MED ;LAFON LABOR (FR))</p> <p>11 January 1989 (1989-01-11)</p> <p>page 2, line 35-53</p> <p>page 7, line 24-27</p> <p>page 7, line 62 -page 8, line 10</p> <p>---</p>	1-13
A	<p>PATENT ABSTRACTS OF JAPAN</p> <p>& JP 08 183740 A (NIPPON STEEL CHEM CO LTD), 16 July 1996 (1996-07-16)</p> <p>abstract</p> <p>---</p>	1-13
A	<p>ITO M ET AL: "T cell adherence and mucosal injury in ulcerative colitis: involvement of integrin-fibronectin interaction in situ."</p> <p>JOURNAL OF GASTROENTEROLOGY. JAPAN NOV 1995,</p> <p>vol. 30 Suppl 8, November 1995 (1995-11), pages 70-72, XP009012797</p> <p>ISSN: 0944-1174</p> <p>page 70</p> <p>-----</p>	1-13

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.1

Although claim 13 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA 03/00066

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 03/00066

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5840691	A	24-11-1998	US 5591719 A EP 0673384 A1 WO 9413692 A1 SG 49017 A1	07-01-1997 27-09-1995 23-06-1994 18-05-1998
EP 0298820	A	11-01-1989	FR 2617170 A1 EP 0298820 A1 JP 1063596 A	30-12-1988 11-01-1989 09-03-1989
JP 08183740	A	16-07-1996	NONE	